Neutralization and hemagglutination-inhibition antibodies following influenza vaccination of HIV-infected and HIV-uninfected pregnant women

Background We previously reported that despite HIV-infected pregnant women had modest humoral immune responses to inactivated influenza vaccine (IIV) measured by hemagglutination-inhibition (HAI) assay, the observed vaccine efficacy against influenza disease was higher than predicted by HAI; suggesting that IIV may confer protection to HIV-infected individuals by additional mechanisms. We evaluated the response to IIV by microneutralization (MN) and HAI assays and correlated both methods in HIV-infected and HIV-uninfected pregnant women. Methods MN and HAI antibodies were measured pre-vaccination and approximately one-month post-vaccination in 80 HIV-infected and 75 HIV-uninfected women who received IIV. Geometric mean titers (GMTs), fold-change in titers and seroconversion rates were determined for the three influenza stains in the vaccine. Results After vaccination there were significant increases in MN and HAI GMTs for the three vaccine strains in both HIV-infected and HIV-uninfected women. HIV-infected women had, however, a lower immune response compared to HIV-uninfected. Fold-increases were 2 to 3-times higher for MN assay compared to HAI assay for the influenza-A strains. Also a higher percentage of women seroconverted by MN than by HAI assay for the influenza-A strains. There was high positive correlation between MN and HAI assays, except for the B/Victoria strain at pre-vaccination. Conclusions In general, the MN assay was more sensitive than the HAI assay. Microneutralization antibodies might correlate better with protection against influenza infection.

[1]  A. Barać,et al.  Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults , 2018, Human vaccines & immunotherapeutics.

[2]  J. Taubenberger,et al.  Evaluation of Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus , 2018, mBio.

[3]  M. Loeb,et al.  Single radial haemolysis compared to haemagglutinin inhibition and microneutralization as a correlate of protection against influenza A H3N2 in children and adolescents , 2017, Influenza and other respiratory viruses.

[4]  S. Madhi,et al.  Risk Factors for Influenza-Associated Severe Acute Respiratory Illness Hospitalization in South Africa, 2012–2015 , 2017, Open forum infectious diseases.

[5]  M. Koopmans,et al.  Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. , 2017, Vaccine.

[6]  David N. Taylor,et al.  Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults. , 2016, Vaccine.

[7]  D. Cummings,et al.  A comparison of hemagglutination inhibition and neutralization assays for characterizing immunity to seasonal influenza A , 2016, Influenza and other respiratory viruses.

[8]  Meeting of the Strategic Advisory Group of Experts on immunization, April 2012--conclusions and recommendations. , 2016, Releve epidemiologique hebdomadaire.

[9]  J. Powers,et al.  Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model , 2016, mBio.

[10]  Stephanie A. Jones,et al.  Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants. , 2015, The Journal of infectious diseases.

[11]  L. Wijnans,et al.  A review of the changes to the licensing of influenza vaccines in Europe , 2015, Influenza and other respiratory viruses.

[12]  A. Monto,et al.  Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. , 2015, The Journal of infectious diseases.

[13]  C. Armon,et al.  Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children. , 2015, Vaccine.

[14]  C. Verschoor,et al.  Microneutralization Assay Titres Correlate with Protection against Seasonal Influenza H1N1 and H3N2 in Children , 2015, PloS one.

[15]  Stephanie A. Jones,et al.  Influenza vaccination of pregnant women and protection of their infants. , 2014, The New England journal of medicine.

[16]  B. Cowling,et al.  Association between antibody titers and protection against influenza virus infection within households. , 2014, The Journal of infectious diseases.

[17]  J. Katz,et al.  Immunological assessment of influenza vaccines and immune correlates of protection , 2013, Expert review of vaccines.

[18]  F. Ennis,et al.  Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals , 2012, Human vaccines & immunotherapeutics.

[19]  J. McCullers,et al.  Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. , 2012, Vaccine.

[20]  L. Eberly,et al.  Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. , 2011, Vaccine.

[21]  C. Tremblay,et al.  Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. , 2011, Vaccine.

[22]  G. Boivin,et al.  Evaluation of Serological Diagnostic Methods for the 2009 Pandemic Influenza A (H1N1) Virus , 2011, Clinical and Vaccine Immunology.

[23]  I. Frank,et al.  Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals , 2010, AIDS.

[24]  René Ecochard,et al.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model , 2010, BMC medical research methodology.

[25]  E. Janoff,et al.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. , 2009, The Lancet. Infectious diseases.

[26]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[27]  R. G. Das,et al.  Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. , 2007, Vaccine.

[28]  A. S. Beare,et al.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses , 1972, Epidemiology and Infection.

[29]  Ross D. Cranston,et al.  Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults. , 2015, American journal of epidemiology.

[30]  Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 – conclusions and recommendations. , 2013, Releve epidemiologique hebdomadaire.

[31]  L. Eberly,et al.  Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  S. Madhi,et al.  Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  A. Osterhaus,et al.  Haemagglutination-inhibiting antibody to influenza virus. , 2003, Developments in biologicals.